4 terminated. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 4 |
| Phase 1 | 1 | Terminated 1 |
Follow Depsipeptides: new trials by email Literature Review of Depsipeptides trials Research Report on Depsipeptides
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer Romidepsin, Abraxane - HER2-negative Breast Cancer, Inflammatory Breast Cancer | Phase 1 / Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 9 | 2014-04-01 | 2025-05-16 |
| Trial of Romidepsin and Bortezomib for Multiple Myeloma Bortezomib, Romidepsin - Multiple Myeloma | Phase 2 | Terminated | Celgene | 32 | 2008-09-01 | 2019-11-25 |
| FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma Depsipeptide - Malignant Melanoma, Melanoma | Phase 2 | Terminated | ECOG-ACRIN Cancer Research Group | 4 | 2005-10-04 | 2023-06-28 |
| S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium Depsipeptide - Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter | Phase 2 | Terminated | SWOG Cancer Research Network | 6 | 2004-06-01 | 2012-11-02 |
Breast Neoplasms (1) · Breast Neoplasms, Male (1) · Inflammatory Breast Neoplasms (1) · Melanoma (1) · Multiple Myeloma (1) · Urethral Neoplasms (1) · Urinary Bladder Neoplasms (1)
Celgene (1) · ECOG-ACRIN Cancer Research Group (1) · SWOG Cancer Research Network (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1)
United States (2)
Daniel P. Petrylak, MD (1) · David H. Lawson, MD (1) · Maysa Abu-khalaf, MD (1) · Tina Neilson (1)
U10CA021115 (1), U10CA032102 (1)